Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Febuxostat 120 mg in Healthy Adults
NCT03918551Phase 1Completed
- Sponsor
- Pharmtechnology
- Start
- May 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of febuxostat in gout (2 arms), sponsored by Pharmtechnology. Primary endpoints: Maximum Plasma Concentration and Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration. Started May 2019; status: completed.
02
Drugs
febuxostat
03
Conditions
gout
Beyond the preview
Go deeper on NCT03918551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03918551.